Get the Stockscreener App
20.81
2.30%
-0.49
After Hours:
20.81
Arrivent Biopharma Inc stock is traded at $20.81, with a volume of 90,314.
It is down -2.30% in the last 24 hours and up +26.74% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$21.30
Open:
$21.16
24h Volume:
90,314
Relative Volume:
0.46
Market Cap:
$712.23M
Revenue:
-
Net Income/Loss:
$-81.05M
P/E Ratio:
-7.9331
EPS:
-2.6232
Net Cash Flow:
$-68.97M
1W Performance:
-0.53%
1M Performance:
+26.74%
6M Performance:
-34.93%
1Y Performance:
+20.78%
1-Day Range:
$20.66
$21.42
1-Week Range:
$19.48
$21.79
52-Week Range:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
20.81 | 712.23M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by Wells Fargo & Company MN - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down – Here’s Why - Defense World
Barclays PLC Grows Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Invesco Ltd. Takes Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by JPMorgan Chase & Co. - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Update - Defense World
Legal & General Group Plc Purchases 10,783 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma Appoints Dr. Merdad Parsey to Board of Directors - MyChesCo
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors - The Manila Times
ArriVent BioPharma appoints new board member By Investing.com - Investing.com South Africa
ArriVent BioPharma appoints new board member - Investing.com Australia
ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors - citybiz
ArriVent BioPharma (AVBP) Strengthens Leadership with New Board Appointment | AVBP Stock News - GuruFocus
Arbutus Biopharma Showcases Promising Hepatitis B Research at EASL Congress - MyChesCo
Learn to Evaluate (AVBP) using the Charts - news.stocktradersdaily.com
Geode Capital Management LLC Cuts Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
In Depth: Popular Overseas Expansion Strategy Holds Pitfalls for Chinese Drug Developers - Caixin Global
Vanguard Group Inc. Has $37.76 Million Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
41,921 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Bought by Wellington Management Group LLP - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Buy” by Brokerages - Defense World
KLP Kapitalforvaltning AS Purchases New Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Corebridge Financial Inc. Has $373,000 Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
(AVBP) Trading Report - news.stocktradersdaily.com
Swiss National Bank Buys Shares of 26,400 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates - MyChesCo
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations - MyChesCo
Charles Schwab Investment Management Inc. Has $5.50 Million Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma (AVBP) Projected to Post Earnings on Thursday - The AM Reporter
Brokers Offer Predictions for AVBP Q1 Earnings - Defense World
Brokerages Set ArriVent BioPharma, Inc. (NASDAQ:AVBP) Target Price at $39.40 - Defense World
B. Riley Begins Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Upgraded at B. Riley - Defense World
B.Riley sets $37 target on ArriVent stock, initiates with Buy - Investing.com Canada
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside - Benzinga
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
B. Riley Initiates ArriVent BioPharma at Buy With $37 Price Target -March 20, 2025 at 07:13 am EDT - MarketScreener
ArriVent Biopharma initiated with a Buy at B. Riley - TipRanks
ArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on Thursday - Defense World
ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
ArriVent BioPharma reports FY results - MSN
Taiho Expands Cancer Pipeline With ADCs In $400m Araris Buy - insights.citeline.com
(AVBP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
ArriVent BioPharma appoints PwC as new auditor - Investing.com India
ArriVent BioPharma appoints PwC as new auditor By Investing.com - Investing.com South Africa
ArriVent BioPharma (NASDAQ:AVBP) Now Covered by Analysts at Guggenheim - Defense World
Oppenheimer starts ArriVent BioPharma at outperform - MSN
Guggenheim starts ArriVent Biopharma with a Buy on firmonertinib potential - TipRanks
Financial Contrast: ArriVent BioPharma (AVBP) and The Competition - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Earns “Buy” Rating from HC Wainwright - Defense World
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength - MSN
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):